BACKGROUND: Cancer of the exocrine pancreas is a highly lethal malignancy. Surgical resection is the only potentially curative treatment. Unfortunately, because of the late presentation, the majority have either locally advanced @entity5 at initial diagnosis. Systemic chemotherapy provides benefit to @entity1 with advanced @entity788 , improving disease-related symptoms and survival when compared to best supportive care alone. Based on fase III study, FOLFIRINOX regimen became the standard first-line treatment. But, the optimal management strategy for @entity1 who fail initial FOLFIRINOX is undefined. Despite the lack of clinical trials that report the real benefit of @entity136 in @entity1 with advanced exocrine @entity788 as second line treatment. We aim at reporting our experience with this regimen. METHODS: @entity1 with advanced exocrine @entity788 who received @entity136 (1.000 mg/m(2) on days 1, 8 and 15 every 4 weeks) until disease progression, as second-line therapy at our institution were retrospectively evaluated. Progression-free survival (PFS) and @entity1349 ( @entity1349 ) were estimated by the Kaplan-Meier method. RESULTS: A total of 20 @entity1 were reviewed. Median age was 57 years (range, 43-74 years), and 55% were older than 60 years. Most @entity1 were male (80%), had @entity3 (60%), and ECOG performance status of 0 or 1 (65%). PFS and @entity1349 were 2.0 (95% CI, 1.2-2.8) and 5.7 months (95% CI, 3.9-7.4), respectively. There were no deaths due to the treatment. CONCLUSIONS: In this study, @entity136 was a reasonable second-line treatment option for @entity1 with advanced @entity788 and good ECOG performance status. Phase III trials are urgently needed comparing @entity136 versus best supportive of care (BSC) can evaluate the real benefit of this chemotherapy after progression on FOLFIRINOX.

Role of @entity136 as second-line therapy after progression on FOLFIRINOX in advanced XXXX : a retrospective analysis.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatic cancer', 'pancreatic adenocarcinoma'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastatic disease'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity788 :: (MESH:D010190,Disease) :: ['pancreatic cancer']
